Instil Bio
26 hedge funds and large institutions have $29.2M invested in Instil Bio in 2026 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 10 closing their positions.
5.8% less ownership
Funds ownership: 61.88% → 56.08% (-5.8%)
15% less capital invested
Capital invested by funds: $34.6M → $29.2M (-$5.33M)
19% less funds holding
Funds holding: 32 → 26 (-6)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
38% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 8
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$1.38M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$347K |
| 3 |
BlackRock
New York
|
+$28.1K |
| 4 |
Millennium Management
New York
|
+$13.1K |
| 5 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
+$4.44K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kalehua Capital Management
Dallas,
Texas
|
-$673K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$216K |
| 3 |
Jane Street
New York
|
-$94.9K |
| 4 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
-$87.5K |
| 5 |
PCM
Prelude Capital Management
New York
|
-$84.9K |
TIL Hedge Fund Activity: Q2 2026 in Review
26 of the 8,317 institutional investors tracked by Wall St. Rank reported a position in Instil Bio (TIL) for Q2 2026, worth a combined $29.2M — down 15% from $34.6M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of TIL and 5 opened new positions — a net loss of 5 holders — while 8 trimmed existing stakes and 5 added.
The largest buyer was UBS Group, adding an estimated $1.38M. The largest seller was Kalehua Capital Management, cutting an estimated $673K.
- 26 institutional investors held Instil Bio (TIL) as of Q2 2026, down from 32 in Q1 2026.
- Funds reported $29.2M of Instil Bio stock for Q2 2026, down 15% quarter-over-quarter.
- 5 funds opened new Instil Bio positions in Q2 2026 and 10 closed out, a net change of -5 holders.
- The largest Instil Bio buyer in Q2 2026 was UBS Group, an estimated $1.38M added.
- The largest Instil Bio seller in Q2 2026 was Kalehua Capital Management, an estimated $673K sold.
Based on aggregated 13F filings for Q2 2026.